Clinical trial · Interventional
Agaricus Blazei Murill in Patients With Multiple Myeloma
Use of the Medicinal Mushroom Agaricus Blazei Murill in Addition to High Dose Chemotherapy in Patients With Multiple Myeloma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Extract from the mushroom Agaricus blazei Murill har been shown to have strong immunomodulating properties both in cell cultures, animal models and in humans. Furthermore antitumor properties have been shown in animal models, among them in mice with multiple myeloma. The investigators now want to investigate the effect of Agaricus as supplementary treatment in addition to chemotherapy in patients with multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intake of 60 ml agaricus daily in addition to chemotherapy | Dietary Supplement | — | UNRESOLVED |
| Intake of 60 ml placebo daily in addition to chemotherapy | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Water with artificial colour
- description
- Placebo
- interventionNames
- Dietary Supplement: Intake of 60 ml placebo daily in addition to chemotherapy
- type
- ACTIVE_COMPARATOR
- label
- Extract of agaricus blazei Murill
- description
- Agaricus blazei Murill
- interventionNames
- Dietary Supplement: Intake of 60 ml agaricus daily in addition to chemotherapy
Primary outcomes (1)
- measure
- Cytokine levels in serum
- timeFrame
- 7 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients scheduled to undergo high dose chemotherapy with autologous stem cell support for multiple myeloma Exclusion Criteria: * None
References
Publications (1)
- DERIVEDTangen JM, Tierens A, Caers J, Binsfeld M, Olstad OK, Troseid AM, Wang J, Tjonnfjord GE, Hetland G. Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int. 2015;2015:718539. doi: 10.1155/2015/718539. Epub 2015 Jan 18. PMID 25664323